CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy

References

• Valerius T, Stockmeyer B, van Spriel AB, Graziano RF, van den Herik-Oudijk IE, Repp R, Deo YM, Lund J, Kalden JR, Gramatzki M, et al. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood. 1997;90:4485-92. PMID:9373259
   PubMed Web of Science ®Google Scholar
• Fan G, Wang Z, Hao M, Li J. Bispecific antibodies and their applications. Journal of hematology & Oncology. 2015;8:130. doi:10.1186/s13045-015-0227-0
   PubMed Web of Science ®Google Scholar
• Chen S, Li J, Li Q, Wang Z. Bispecific antibodies in cancer immunotherapy. Human vaccines & immunotherapeutics. 2016;12:2491-500. doi:10.1080/21645515.2016.1187802
   PubMed Web of Science ®Google Scholar
• Kiefer JD, Neri D. Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site. Immunol Rev. 2016;270:178-92. doi:10.1111/imr.12391. PMID:26864112
   PubMed Web of Science ®Google Scholar
• Compte M, Alvarez-Cienfuegos A, Nunez-Prado N, Sainz-Pastor N, Blanco-Toribio A, Pescador N, Sanz L, Alvarez-Vallina L. Functional comparison of single-chain and two-chain anti-CD3-based bispecific antibodies in gene immunotherapy applications. Oncoimmunology. 2014;3:e28810. doi:10.4161/onci.28810. PMID:25057445
   PubMed Web of Science ®Google Scholar
• Deo YM, Graziano RF, Repp R, van de Winkel JG. Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies. Immunol Today. 1997;18:127-35. doi:10.1016/S0167-5699(97)01007-4. PMID:9078685
   PubMedGoogle Scholar
• Guyre PM, Graziano RF, Vance BA, Morganelli PM, Fanger MW. Monoclonal antibodies that bind to distinct epitopes on Fc gamma RI are able to trigger receptor function. J Immunol. 1989;143:1650-5.
   PubMed Web of Science ®Google Scholar
• Morton HC, van Egmond M, van de Winkel JG. Structure and function of human IgA Fc receptors (Fc alpha R). Critical Rev Immunol. 1996;16:423-40. PMID:8954257
   PubMed Web of Science ®Google Scholar
• Stockmeyer B, Dechant M, van Egmond M, Tutt AL, Sundarapandiyan K, Graziano RF, Repp R, Kalden JR, Gramatzki M, Glennie MJ, et al. Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy. J Immunol. 2000;165:5954-61. doi:10.4049/jimmunol.165.10.5954. PMID:11067958
   PubMed Web of Science ®Google Scholar
• van Egmond M, van Spriel AB, Vermeulen H, Huls G, van Garderen E, van de Winkel JG. Enhancement of polymorphonuclear cell-mediated tumor cell killing on simultaneous engagement of fcgammaRI (CD64) and fcalphaRI (CD89). Cancer Res. 2001;61:4055-60. PMID:11358825
   PubMed Web of Science ®Google Scholar
• Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49-61. doi:10.1016/j.immuni.2014.06.010. PMID:25035953
   PubMed Web of Science ®Google Scholar
• Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science. 2013;339:286-91. doi:10.1126/science.1232227. PMID:23329041
   PubMed Web of Science ®Google Scholar
• Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39-51. doi:10.1016/j.cell.2010.03.014. PMID:20371344
   PubMed Web of Science ®Google Scholar
• Fukuda K, Kobayashi A, Watabe K. The role of tumor-associated macrophage in tumor progression. Frontiers in bioscience. 2012;4:787-98.
   Google Scholar
• Ridgway JB, Presta LG, Carter P. ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Prot Eng. 1996;9:617-21. doi:10.1093/protein/9.7.617. PMID:8844834
   PubMedGoogle Scholar
• Li B, Xu L, Tao F, Xie K, Wu Z, Li Y, Li J, Chen K, Pi C, Mendelsohn A, et al. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo. Oncotarget. 2017;8:39356-39366. doi: 10.18632/oncotarget.17000. PMID:28454118
   PubMed Web of Science ®Google Scholar
• Boross P, Lohse S, Nederend M, Jansen JH, van Tetering G, Dechant M, Peipp M, Royle L, Liew LP, Boon L, et al. IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol Med. 2013;5:1213-26. doi:10.1002/emmm.201201929. PMID:23918228
   PubMed Web of Science ®Google Scholar
• Xu L, Li B, Huang M, Xie K, Li D, Li Y, Gu H, Fang J. Critical Role of Kupffer Cell CD89 Expression in Experimental IgA Nephropathy. PloS one. 2016;11:e0159426. doi:10.1371/journal.pone.0159426. PMID:27437939
   PubMed Web of Science ®Google Scholar
• Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47:115-23. doi:10.1053/j.seminhematol.2010.01.011. PMID:20350658
   PubMed Web of Science ®Google Scholar
• Haas C, Krinner E, Brischwein K, Hoffmann P, Lutterbuse R, Schlereth B, Kufer P, Baeuerle PA. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology. 2009;214:441-53. doi:10.1016/j.imbio.2008.11.014. PMID:19157637
   PubMed Web of Science ®Google Scholar
• Algars A, Irjala H, Vaittinen S, Huhtinen H, Sundstrom J, Salmi M, Ristamäki R, Jalkanen S. Type and location of tumor-infiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients. Int J Cancer. 2012;131:864-73. doi:10.1002/ijc.26457. PMID:21952788
   PubMed Web of Science ®Google Scholar
• Laoui D, Movahedi K, Van Overmeire E, Van den Bossche J, Schouppe E, Mommer C, Nikolaou A, Morias Y, De Baetselier P, Van Ginderachter JA. Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. Int J Dev Biol. 2011;55:861-7. doi:10.1387/ijdb.113371dl. PMID:22161841
   PubMed Web of Science ®Google Scholar
• Guo Q, Jin Z, Yuan Y, Liu R, Xu T, Wei H, Xu X, He S, Chen S, Shi Z, et al. New Mechanisms of Tumor-Associated Macrophages on Promoting Tumor Progression: Recent Research Advances and Potential Targets for Tumor Immunotherapy. J Immunol Res. 2016;2016:9720912. doi:10.1155/2016/9720912. PMID:27975071
   PubMed Web of Science ®Google Scholar
• Lohse S, Brunke C, Derer S, Peipp M, Boross P, Kellner C, Beyer T, Dechant M, van der Winkel JG, Leusen JH, et al. Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages. J Biol Chem. 2012;287:25139-50. doi:10.1074/jbc.M112.353060. PMID:22679018
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Dual targeting strategies with bispecific antibodies. mAbs. 2012;4:182-97. doi:10.4161/mabs.4.2.19000. PMID:22453100
   PubMed Web of Science ®Google Scholar
• Satta A, Mezzanzanica D, Turatti F, Canevari S, Figini M. Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors. Future Oncology. 2013;9:527-39. doi:10.2217/fon.12.203. PMID:23560375
   PubMed Web of Science ®Google Scholar
• Zugmaier G, Klinger M, Schmidt M, Subklewe M. Clinical overview of anti-CD19 BiTE((R)) and ex vivo data from anti-CD33 BiTE((R)) as examples for retargeting T cells in hematologic malignancies. Mol Immunol. 2015;67:58-66. doi:10.1016/j.molimm.2015.02.033. PMID:25883042
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE. The making of bispecific antibodies. mAbs. 2017;9:182-212. doi:10.1080/19420862.2016.1268307. PMID:28071970
   PubMed Web of Science ®Google Scholar
• Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol. 2015;67:95-106. doi:10.1016/j.molimm.2015.01.003. PMID:25637431
   PubMed Web of Science ®Google Scholar
• Shatz W, Chung S, Li B, Marshall B, Tejada M, Phung W, Sandoval W, Kelley RF, Scheer JM. Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity. mAbs. 2013;5:872-81. doi:10.4161/mabs.26307. PMID:23995614
   PubMed Web of Science ®Google Scholar
• Stockmeyer B, Valerius T, Repp R, Heijnen IA, Buhring HJ, Deo YM, Kalden JR, Gramatzki M, van de Winkel JG. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. Cancer Res. 1997;57:696-701. PMID:9044847
   PubMed Web of Science ®Google Scholar
• Deo YM, Sundarapandiyan K, Keler T, Wallace PK, Graziano RF. Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood. J Immunol. 1998;160:1677-86.
   PubMed Web of Science ®Google Scholar
• Gul N, van Egmond M. Antibody-Dependent Phagocytosis of Tumor Cells by Macrophages: A Potent Effector Mechanism of Monoclonal Antibody Therapy of Cancer. Cancer Res. 2015;75:5008-13. doi:10.1158/0008-5472.CAN-15-1330. PMID:26573795
   PubMed Web of Science ®Google Scholar
• Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015;27:462-72. doi:10.1016/j.ccell.2015.02.015. PMID:25858805
   PubMed Web of Science ®Google Scholar
• Guettinger Y, Barbin K, Peipp M, Bruenke J, Dechant M, Horner H, Thierschmidt D, Valerius T, Repp R, Fey GH, et al. A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells. J Immunol. 2010;184:1210-7. doi:10.4049/jimmunol.0902033. PMID:20042573
   PubMed Web of Science ®Google Scholar
• Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P. An efficient route to human bispecific IgG. Nat Biotechnol. 1998;16:677-81. doi:10.1038/nbt0798-677. PMID:9661204
   PubMed Web of Science ®Google Scholar
• Kreuer S, Hauschild A, Fink T, Baumbach JI, Maddula S, Volk T. Two different approaches for pharmacokinetic modeling of exhaled drug concentrations. Sci Rep. 2014;4:5423. doi:10.1038/srep05423. PMID:24957852
   PubMed Web of Science ®Google Scholar